You are here

Article Text

Article menu
Download PDFPDF
Correspondence
Lymphocyte phenotypes in systemic sclerosis
  1. EDIZ DALKILIÇ,
  2. KAMIL DILEK,
  3. MUSTAFA GÜLLÜLÜ,
  4. MAHMUT YAVUZ,
  5. YÜKSEL KARAKOÇ,
  6. MUSTAFA YURTKURAN
  1. FERAH BUDAK,
  2. GÜHER GÖRAL
  1. Uludag University, School of Medicine, Department of Rheumatology and Nephrology
  2. Uludag University, School of Medicine, Department of Infectious Disease
  1. Dr K Dilek, Uludag University Medical Faculty, Department of Nephrology and Rheumatology 16059, Görükle-Bursa, Turkey.

https://doi.org/10.1136/ard.58.11.719a

Statistics from Altmetric.com

    Request Permissions

    If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

    Although the pathophysiology of systemic sclerosis (SSc) is not fully clarified, there are considerable data implicating abnormalities of microvascular changes, fibroblast activation and immune system abnormalities. Immune system activation may play a part as a stimulus in both fibrotic and vascular damage.1 To investigate the immune system abnormalities in the pathogenesis of SSc we evaluated lymphocyte phenotypes in patients with SSc and healthy controls by flow cytometry (Epics Profile II) for total T (CD3), T helper (CD4), T supressor (CD8), B lymphocyte cell surface marker (CD19), activation marker (CD25) and natural killer (NK) cell surface marker NKH-1 (CD56).

    We studied 29 patients (27 women, two men) 16 limited, 12 diffuse and one overlap who fulfilled preliminary criteria for classification of SSc.2 Anti-nuclear antibody was positive in 25 (86.2%) and anti-Scl70 antibodies was positive in seven (24.1 %) patients. The age range of the patients was 20–63 years (mean (SEM) 40 (5)) and the mean (SEM) disease duration was 5.6 (5.5) years. …

    View Full Text